domingo, 22 de noviembre de 2026
Implanted device offers new treatment option for rheumatoid arthritis
https://www.news-medical.net/news/20261120/Implanted-device-offers-new-treatment-option-for-rheumatoid-arthritis.aspx
A new treatment for rheumatoid arthritis that uses a small, implanted device to help control inflammation is now available to patients in Michigan through Henry Ford Health's neurosurgery team.
The wireless device, about the size of a multivitamin, is implanted on the vagus nerve and uses electrical stimulation to activate the body's natural response to inflammation, helping ease the inflammation that causes joint pain, swelling and stiffness in rheumatoid arthritis.
Dr. Ellen Air, functional neurosurgeon and chair of the Department of Neurosurgery at Henry Ford Health, completed the state's first commercial implantation of the device on Oct. 26 at Henry Ford Hospital in Detroit. The patient, Kim Landrith, 71, of Macomb County, had the device activated Nov. 11.
ATRX loss may guide targeted treatment for aggressive sarcomas
https://www.news-medical.net/news/20261120/ATRX-loss-may-guide-targeted-treatment-for-aggressive-sarcomas.aspx
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.
The study, published in The Journal of Clinical Investigation, was led by Kunal Rai, Ph.D., professor of Genomic Medicine. If validated in future clinical trials, the results suggest ATRX – one of the most commonly mutated genes in sarcoma – could be a potential biomarker to guide treatment selection for patients with soft-tissue sarcomas.
"For many patients with sarcoma, treatment decisions still are not guided by the biology of their tumors," Rai said. "We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers."
Study reveals why Ebola virus causes severe disease in humans
https://www.news-medical.net/news/20261120/Study-reveals-why-Ebola-virus-causes-severe-disease-in-humans.aspx
Illnesses from Ebola virus and its relatives have about a 50 percent fatality rate in humans. The current outbreak in the Democratic Republic of Congo has already caused over 10,500 confirmed cases and over 5,130 deaths, according to the U.S. Centers for Disease Control and Prevention.
Ebola virus is a devastating pathogen. Like humans, bats can get infected with Ebola virus. So why don't bats get sick?
"Another puzzle," says lead author LJI Professor, President & CEO Erica Ollmann Saphire, Ph.D., MBA. "is why humans do get so sick. And why the worst cases can have the strongest inflammatory responses. These are strong immune responses, but they're not working well."
Rheumatology (+...)
https://www.medscape.com/rheumatology
Rheumatology News
Deucravacitinib Linked to Arthritis Improvements in SLE
Deucravacitinib is associated with improvements in arthritis manifestations among patients with systemic lupus erythematosus at week 48, per a post hoc analysis of a phase 2 study.
Medscape Medical News, November 20, 2026
https://www.medscape.com/index/list_11823_0
Gastroenterology News: Endoscopist Skill, Polyp Findings Tied to CRC Risk (+... +... +...)
Gastroenterology News
Endoscopist Skill, Polyp Findings Tied to CRC Risk
Lower endoscopist adenoma detection rates and high-risk polyp findings are independently and jointly associated with higher risk for post-colonoscopy colorectal cancer.
Medscape Medical News, November 20, 2026
https://www.medscape.com/index/list_11601_0
Gastroenterology Perspective
Retatrutide vs Semaglutide for People With Type 2 Diabetes
Dr Anne Peters discusses recent data on retatrutide vs semaglutide for people with type 2 diabetes.
Medscape Diabetes & Endocrinology, November 20, 2026
https://www.medscape.com/index/list_13288_0
Gastroenterology Cases & Quizzes
Gallstone-Related Abscess in a Man 11 Years After Surgery
A 68-year-old man develops thoracic pain and recurrent fever 11 years after laparoscopic cholecystectomy; imaging reveals a perihepatic abscess linked to a gallstone.
Medscape Europe, November 15, 2026
https://www.medscape.com/index/list_11612_0
Suscribirse a:
Entradas (Atom)

